PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.41
Negative OCF/share while Biotechnology median is -0.27. Seth Klarman would examine if a turnaround is realistic.
-0.41
Negative FCF/share while Biotechnology median is -0.29. Seth Klarman would question if the business is too capex-heavy.
-0.27%
Negative ratio while Biotechnology median is -0.08%. Seth Klarman would examine if negative OCF or unusual accounting drives this figure.
0.84
Ratio near Biotechnology median of 0.77. Charlie Munger might see standard alignment across the industry.
No Data
No Data available this quarter, please select a different quarter.